John R. T. Monson, MD

John R. T. Monson, MD

Executive Medical Director Digestive Health and Surgery Institute

Cancer, Digestive Health and Surgery

John Monson

Overview

Dr. Monson is a board-certified colon and rectal surgeon with advanced fellowship training in surgical oncology, vascular surgery and colon and rectal surgery. His areas of expertise include the use of minimally invasive technologies in colorectal cancer treatment, including transanal endoscopic microsurgery (TEMS), laparoscopy and robotic surgery. In addition to his role as a leading physician with the AdventHealth Medical Group's elite colorectal surgery team, he also serves as Executive Director for Colorectal Surgery at AdventHealth in Orlando. Dr. Monson is credited with leading the development of laparoscopic colorectal surgery in the United Kingdom, and he is a former Chair of the U.K.'s National Training Program. His research encompasses a broad range of cancer-related areas including the development of national standards and qualitative assessments of decision-making in cancer care.

Awards & Recognition
He was the secretary to the Irish Higher Surgical Training Group, representing trainees on the National Council. His final year project won the Dr. Pamela Gilligan Prize in Sept 2016. Since coming to Florida, he has involved himself with myriad projects including being on the steering committee for AdventHealth to achieve National Accreditation for Rectal Cancer. He has authored over 35 original published papers, 4 books and 5 book chapters.

Articles

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Systematic Review.

Diseases of the colon and rectum

2022

Development and evaluation of a virtual knowledge assessment tool for transanal total mesorectal excision

Techniques in Coloproctology

2022

Lateral lymph node dissection and urogenital function with and without neoadjuvant treatment

TRANSLATIONAL CANCER RESEARCH

2022

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Systematic Review

DISEASES OF THE COLON & RECTUM

2022

V-Y Gluteal Fasciocutaneous Advancement Flap After Robotic Abdominoperineal Resection

DISEASES OF THE COLON & RECTUM

2021

Characteristics of Early-Onset vs Late-Onset Colorectal Cancer A Review

JAMA SURGERY

2021

Impact of Bacillus Calmette-Guerin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection

BJS OPEN

2021

Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: the COVIDSurg mortality score

BRITISH JOURNAL OF SURGERY

2021

A Snapshot of the International Views of the Treatment of Rectal Cancer Patients, a Multi-regional Survey: International Tendencies in Rectal Cancer

WORLD JOURNAL OF SURGERY

2020

Achieving Opioid-Free Major Colorectal Surgery: Is It Possible?

DIGESTIVE SURGERY

2020

More Publication Information

Education & Training

Education

Trinity College School of Medicine Dublin Ireland

Residency

Royal College of Surgeons & St. James University Leeds UK

Fellowship

Royal College of Surgeons in Ireland, Dublin, Ireland; Surgical Oncology, Mayo Clinic, Rochester, MN

Specialty

Colon and Rectal Surgery

Board Certifications

American Board of Colon and Rectal Surgery

Associated Clinical Trials

NCT03279081

A Phase III, Randomized, Double Blind, Parallel Group, Placebo Controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-Derived Stem Cells (eASC), for the Treatment of Complex Perianal Fistula(s) in Patients with Crohn's Disease Over a Period of 24 Weeks and a Follow-Up Period Up to 52 Weeks. ADMIRE-CD II Study.

Icon for trial | Cx601-0303 A Phase III, Randomized, Double Blind, Parallel Group, Placebo Controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-Derived Stem Cells (eASC), for the Treatment of Complex Perian

This study is currently enrolling.

The purpose of this study is to confirm (1) how well the study drug works at a single dose of 120 million cells compared to a placebo; (2) how safe and tolerable the study drug is in patients with fistulizing CD.